FDA Clears Long Bridge Medical to Launch GOLDEN GATE Pivotal Trial for LensOne™ Prosthetic Capsular Bag
Long Bridge Medical, Inc., a U.S.-based medical device innovator focused on advancing ophthalmic surgical solutions, has announced a major regulatory milestone with the U.S. Food and Drug Administration (FDA) granting clearance to initiate its pivotal clinical study for LensOne™, an investigational prosthetic capsular bag. The study will be conducted under an Investigational Device Exemption (IDE), enabling the company to begin a large-scale clinical evaluation of the device across multiple sites in the United States.
This development marks a significant step forward in addressing a long-standing clinical challenge in ophthalmology—managing patients who require secondary intraocular lens (IOL) implantation but lack sufficient capsular support. These patients often present complex cases due to conditions such as post-surgical aphakia, ocular trauma, or spontaneous IOL dislocation, and they typically have limited treatment options that are both safe and effective.
Addressing a Critical Unmet Need
In a standard cataract surgery, the natural lens of the eye is removed and replaced with an artificial intraocular lens, which is typically anchored within the capsular bag—a thin membrane that once enclosed the natural lens. However, in certain patients, this capsular support is either absent or compromised, making traditional IOL placement difficult or impossible.
For such individuals, surgeons must rely on alternative fixation techniques, including anterior chamber intraocular lenses (ACIOLs), scleral-sutured IOLs, or sutureless intrascleral fixation methods such as the Yamane technique. While these approaches can be effective, they are often technically demanding and associated with increased risks, including lens instability, corneal damage, glaucoma, retinal detachment, and long-term complications.
LensOne™ has been developed specifically to address these limitations. The device functions as a prosthetic capsular bag, effectively recreating the natural anatomical structure needed to securely hold an intraocular lens in place. By restoring this structural support, LensOne aims to provide surgeons with a more predictable and standardized method for IOL fixation, ultimately improving patient outcomes.
FDA IDE Clearance and the GOLDEN GATE Trial
The FDA’s clearance of the IDE application allows Long Bridge Medical to initiate the GOLDEN GATE pivotal trial, a prospective, multicenter clinical study designed to evaluate the safety and effectiveness of LensOne™ in a larger patient population.
The GOLDEN GATE trial will enroll patients who have experienced IOL dislocation or require secondary IOL implantation but are not suitable candidates for ACIOLs. These patients represent a particularly vulnerable group with limited FDA-approved treatment options, underscoring the importance of developing new solutions tailored to their needs.
The study will assess key endpoints related to device safety, visual outcomes, stability of lens fixation, and complication rates. By generating robust clinical data, the trial aims to support future regulatory approval and establish LensOne™ as a new standard of care in complex ophthalmic surgeries.
Breakthrough Device Designation
The IDE clearance builds upon an earlier recognition by the FDA, which granted LensOne™ Breakthrough Device Designation. This designation is reserved for medical devices that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions.
The Breakthrough Device program is designed to expedite the development and review process, ensuring that promising technologies reach patients more quickly. In the case of LensOne™, the designation highlights the significant unmet need it addresses and its potential to transform the management of patients with inadequate capsular support.
Clinical Evidence and Early Results
Prior to receiving IDE clearance, Long Bridge Medical conducted a first-in-human clinical study involving 15 patients. The study evaluated the safety and performance of LensOne™ over a 12-month follow-up period.
Results from this early study demonstrated a favorable safety profile, with no unexpected adverse events reported. Additionally, the device showed promising performance in terms of lens stability and visual outcomes, providing confidence in its potential for broader clinical application.
These findings were presented in 2025 at the annual meeting of the American Society of Retina Specialists (ASRS) by Dr. J. Michael Jumper, a leading expert in the field and President of the organization. The presentation generated significant interest within the ophthalmology community, further validating the importance of advancing this technology through a larger, pivotal trial.
Expert Perspective
Dr. Frank Brodie, Co-Founder of Long Bridge Medical, emphasized the importance of this milestone for both the company and patients.
“This IDE approval is a pivotal moment for Long Bridge Medical and, more importantly, for the patients who need better options,” he said. “We have seen firsthand how challenging these cases are for surgeons and how the off-label options currently used often lead to suboptimal outcomes.”
He added that LensOne™ was designed with the goal of providing a reliable and reproducible solution that simplifies surgical procedures while enhancing patient safety and visual outcomes.
“With the GOLDEN GATE trial, we now have the opportunity to generate the clinical evidence needed to support a new standard of care for these complex cases,” Dr. Brodie noted.
Potential Impact on Ophthalmic Surgery
If successful, LensOne™ could represent a paradigm shift in the way ophthalmologists approach secondary IOL implantation. By offering a device that restores the natural architecture of the eye, the technology has the potential to reduce surgical complexity and improve consistency across procedures.
This could be particularly beneficial in reducing variability in outcomes, which is a known challenge with current techniques that depend heavily on surgeon skill and experience. A standardized solution like LensOne™ may also expand access to effective treatment, enabling more surgeons to confidently manage complex cases.
Furthermore, improved lens stability and reduced complication rates could lead to better long-term visual outcomes for patients, enhancing their quality of life.
Looking Ahead
The initiation of the GOLDEN GATE pivotal trial marks the beginning of the next phase in LensOne™’s clinical development. As the study progresses, Long Bridge Medical will work closely with clinical investigators, regulatory authorities, and the broader ophthalmology community to ensure rigorous evaluation and transparency.
The results of this trial will be critical in determining the device’s future, including potential FDA approval and commercialization. If approved, LensOne™ could fill a significant gap in the current treatment landscape and provide a much-needed option for patients with limited alternatives.
Conclusion
The FDA’s clearance for Long Bridge Medical to begin its pivotal clinical trial represents a major advancement in ophthalmic innovation. With the potential to address a critical unmet need, LensOne™ offers hope for improved treatment options in patients requiring secondary intraocular lens fixation.
As the GOLDEN GATE trial gets underway, the medical community will be watching closely to see whether this novel prosthetic capsular bag can deliver on its promise of safer, more effective, and more predictable surgical outcomes.
About LensOne
LensOne is an investigational, prosthetic capsular bag designed to restore the anatomic foundation needed for standard IOL implantation in eyes lacking capsule support who are poor candidates for ACIOL. Designed to support a variety of IOL types, LensOne enables surgeons to use familiar techniques in complex cases previously requiring high-risk surgical alternatives. CAUTION—Investigational device. Limited by United States law to investigational use.
About Long Bridge Medical
Long Bridge Medical is a South San Francisco-based ophthalmic device company developing solutions for complex IOL fixation. The company is backed by leading ophthalmic surgeons and life science investors committed to advancing vision care.
